An interventional study of STROKE 120 multifaceted intervention campaign in Ischemic Stroke, sponsored by Shanghai Minhang Central Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shanghai Minhang Central Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 754 studies in Ischemic Stroke with a site in China, this one has the largest planned enrollment of the 566 interventional ones that give a count, is one of 107 that started in 2025, is one of 247 with no phase, reaches primary completion later than 182 of the 399 other live ones, and was the 587th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
754 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 107 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,696,000 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 271 across the 566 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 11 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 754 have an industry lead sponsor. The 10 most frequent:
Shanghai Minhang Central Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Shanghai Minhang Central Hospital has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
108 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 22 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
Add all 108 to your calendar (.ics) → With an account.
Among the 754 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke is the main cause of death and disability in China, but it is preventable and treatable. For the most common type, acute ischemic stroke (AIS), initiating reperfusion therapy with intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT) within several hours of the onset of symptoms can significantly improve the chances of surviving free of major disability, and earlier the intervention is given the better the outcome. Thus, whether patients can achieve timely arrived at hospital, ideally within the critical 4.5-hour golden window, is pivotal to achieving high rates of recanalization and optimal functional outcome. To this end, it is important to note that the overall pre-hospital delay for patients with AIS is currently 24 hours in China.
We plan to conduct STROKE 120 ACTION, a national cluster randomized controlled trial, to determine whether implementing a STROKE 120 multifaceted intervention campaign can reduce pre-hospital delay in AIS, increase the 4.5-hour hospital arrival rate, and improve survival, disability, and healthcare costs. The STROKE 120 ACTION trial will recruit 16 community units across 8 regions in China, with each region enrolling 2 community units with a residential population of at least 110,000 and comparable demographic characteristics. To avoid cross-contamination, the participating community clusters will maintain a physical distance of more than 20 kilometers. Within each region, the 2 community units will be randomly assigned at a 1:1 ratio to receive the intervention (12-month usual health policy plus STROKE 120 multifaceted intervention campaign; 3-month intensive period and 9-month maintenance period) or control (12-month usual health policy alone). The study outcomes and related data on incident AIS cases within each participating community unit will be collected after the implementation of STROKE 120 multifaceted intervention campaign (from month 1 to month 12 of multifaceted intervention campaign). The primary outcome is proportion of hospital arrival within 4.5 hours after symptom onset within participating community units. Secondary outcomes include time from onset to hospital admission, time from onset to action, use of 120 emergency ambulances, IVT, MT, total hospitalization costs, out-of-pocket costs, composite outcome of death or major disability (modified Rankin scale score [mRS] ≥3) at 3 months, ordinal 7-level mRS score at 3 months, all-cause mortality within 3 months. The sample size was calculated according to the following estimates: (1) a significance level of 0.05 for a 2-sided test; (2) statistical power of 85%; (3) 4.5-hour hospital arrival rate of 10% for AIS patients in control group; (4) 4.5-hour hospital arrival rate of 20% among AIS patients in intervention group; (5) intra-class correlation coefficient of 0.03; and (6) a 10% loss to follow-up. The estimated sample size is 3,312 incident AIS patients from 16 community units with an average cluster size of 207 patients per community unit. The annual incidence of AIS is 195 per 100,000 people, and the sample size of participants in each community unit will be 106,000. Thus, the total sample size of the present study will be 1,696,000 participants from 16 community units.
The STROKE 120 ACTION trial will address the critical issue of long pre-hospital delay in AIS in China, and provide profound implications for global stroke prevention and control strategies.
The criteria were revised on the registry on Nov 16, 2026. See what changed
This trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group.
The selection criteria for community units are listed as follows:
The inclusion criteria for registering cases are listed as follows:
Usual health policy plus STROKE 120 multifaceted intervention campaign
Behavioral: STROKE 120 multifaceted intervention campaign
Usual health policy alone
Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period). The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows: 1. Training medical workers in stroke center; 2. Training emergency center staff and primary care physicians; 3. Conducting public education;
Arriving hospital within 4.5 hours after symptom onset among incident acute ischemic stroke cases within participating community units
Proportion of arriving hospital within 4.5 hours after symptom onset among incident acute ischemic stroke cases within participating community units
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Time from onset to hospital admission after acute ischemic stroke
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Time from onset to action after acute ischemic stroke
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Use of 120 emergency ambulances after acute ischemic stroke
Proportion of using 120 emergency ambulances after acute ischemic stroke
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Intravenous thrombolysis after acute ischemic stroke
Proportion of intravenous thrombolysis after acute ischemic stroke
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Mechanical thrombectomy after acute ischemic stroke
Proportion of mechanical thrombectomy after acute ischemic stroke
Time frame: From month 1 to month 12 of multifaceted intervention campaign
Total hospitalization costs
Time frame: At Hospital Discharge after ischemic stroke onset (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)
Out-of-pocket hospitalization costs
Time frame: At Hospital Discharge after ischemic stroke onset (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)
Composite outcome of death or major disability at 3 months after acute ischemic stroke
The composite outcome of death or major disability was defined as a score of 3 to 6 on the modified Rankin Scale at 3 months after ischemic stroke. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.
Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)
Ordinal 7-level modified Rankin Scale score at 3 months after acute ischemic stroke
Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death.
Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)
All-cause mortality within 3 months after acute ischemic stroke
Time frame: Three months after ischemic stroke (ischemic stroke patients occurring from month 1 to month 12 of multifaceted intervention campaign)
Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 13 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2026 → Jan 2027 and completion Feb 2027 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Minhang Central Hospital